Dosing and Safety of Once-Weekly Rifapentine and Isoniazid for 12 Weeks for Tuberculosis Preventive Therapy in Children With and Without HIV: Protocol for a Phase I/II Open-Label, Exposure-Controlled, Dose-Finding, and Safety Study (Tuberculosis Trials Consortium Study 35).

Journal:

JMIR research protocols, Volume: 15

Published:

September 30, 2026

PMID:

42814651

Authors:

Ingrid Courtney I, Meredith G Dixon MG, Louvina van der Laan L, Rada Savic R, Belen Solans B, Kelly Dooley K, Deron Burton D, Shaun Barnabas S, Avy Violari A, Kia Bryant K, Nigel Scott N, Patrick Phillips P, Erin Sizemore E, Wendy Carr W, Susan Purchase S, Elri Nortier E, Joh-Nell van der Westhuizen JN, Anne-Marie Demers AM, Anneke Hesseling A, Rosanna Boyd R

Access Paper

DOI: 10.2196/103274

PMID: 42814651

Abstract:

Young children with exposure to or infection with are at high risk of developing tuberculosis disease, and postexposure tuberculosis preventive treatment decreases this risk. Evidence is limited regarding the dosing and safety of the 12-dose once-weekly rifapentine and isoniazid regimen (3HP) for tuberculosis preventive treatment in children younger than 2 years and in children living with HIV.

Courtesy of the U.S. National Library of Medicine